A pan-PPAR agonist E17241 ameliorates hyperglycemia and diabetic dyslipidemia in KKAy mice via up-regulating ABCA1 in islet, liver, and white adipose tissue
Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved..
OBJECTIVE: Type 2 diabetes mellitus (T2DM) is a common chronic metabolic disease. Peroxisome proliferator-activated receptors (PPARs) play crucial roles in regulating glucolipid metabolism. Previous studies showed that E17241 could ameliorate atherosclerosis and lower fasting blood glucose levels in ApoE-/- mice. In this work, we investigated the role of E17241 in glycolipid metabolism in diabetic KKAy mice.
APPROACH AND RESULTS: We confirmed that E17241 is a powerful pan-PPAR agonist with a potent agonistic activity on PPARγ, a high activity on PPARα, and a moderate activity on PPARδ. E17241 also significantly increased the protein expression of ATP-binding cassette transporter 1 (ABCA1), a crucial downstream target gene for PPARs. E17241 clearly lowered plasma glucose levels, improved OGTT and ITT, decreased islet cholesterol content, improved β-cell function, and promoted insulin secretion in KKAy mice. Moreover, E17241 could significantly lower plasma total cholesterol and triglyceride levels, reduce liver lipid deposition, and improve the adipocyte hypertrophy and the inflammatory response in epididymal white adipose tissue. Further mechanistic studies indicated that E17241 boosts cholesterol efflux and insulin secretion in an ABCA1 dependent manner. RNA-seq and qRT-PCR analysis demonstrated that E17241 induced different expression of PPAR target genes in liver and adipose tissue differently from the PPARγ agonist rosiglitazone. In addition, E17241 treatment was also demonstrated to have an exhilarating cardiorenal benefits.
CONCLUSIONS: Our results demonstrate that E17241 regulates glucolipid metabolism in KKAy diabetic mice while having cardiorenal benefits without inducing weight gain. It is a promising drug candidate for the treatment of T2DM.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:172 |
|---|---|
| Enthalten in: |
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 172(2024) vom: 27. März, Seite 116220 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sheng, Ren [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
97C5T2UQ7J |
|---|
| Anmerkungen: |
Date Completed 04.03.2024 Date Revised 04.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.biopha.2024.116220 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367984539 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367984539 | ||
| 003 | DE-627 | ||
| 005 | 20240304232418.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240204s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.biopha.2024.116220 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1316.xml |
| 035 | |a (DE-627)NLM367984539 | ||
| 035 | |a (NLM)38308968 | ||
| 035 | |a (PII)S0753-3322(24)00101-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sheng, Ren |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A pan-PPAR agonist E17241 ameliorates hyperglycemia and diabetic dyslipidemia in KKAy mice via up-regulating ABCA1 in islet, liver, and white adipose tissue |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.03.2024 | ||
| 500 | |a Date Revised 04.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved. | ||
| 520 | |a OBJECTIVE: Type 2 diabetes mellitus (T2DM) is a common chronic metabolic disease. Peroxisome proliferator-activated receptors (PPARs) play crucial roles in regulating glucolipid metabolism. Previous studies showed that E17241 could ameliorate atherosclerosis and lower fasting blood glucose levels in ApoE-/- mice. In this work, we investigated the role of E17241 in glycolipid metabolism in diabetic KKAy mice | ||
| 520 | |a APPROACH AND RESULTS: We confirmed that E17241 is a powerful pan-PPAR agonist with a potent agonistic activity on PPARγ, a high activity on PPARα, and a moderate activity on PPARδ. E17241 also significantly increased the protein expression of ATP-binding cassette transporter 1 (ABCA1), a crucial downstream target gene for PPARs. E17241 clearly lowered plasma glucose levels, improved OGTT and ITT, decreased islet cholesterol content, improved β-cell function, and promoted insulin secretion in KKAy mice. Moreover, E17241 could significantly lower plasma total cholesterol and triglyceride levels, reduce liver lipid deposition, and improve the adipocyte hypertrophy and the inflammatory response in epididymal white adipose tissue. Further mechanistic studies indicated that E17241 boosts cholesterol efflux and insulin secretion in an ABCA1 dependent manner. RNA-seq and qRT-PCR analysis demonstrated that E17241 induced different expression of PPAR target genes in liver and adipose tissue differently from the PPARγ agonist rosiglitazone. In addition, E17241 treatment was also demonstrated to have an exhilarating cardiorenal benefits | ||
| 520 | |a CONCLUSIONS: Our results demonstrate that E17241 regulates glucolipid metabolism in KKAy diabetic mice while having cardiorenal benefits without inducing weight gain. It is a promising drug candidate for the treatment of T2DM | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ABCA1 | |
| 650 | 4 | |a Diabetic dyslipidemia | |
| 650 | 4 | |a Pan-PPAR agonist | |
| 650 | 4 | |a T2DM | |
| 650 | 7 | |a PPAR gamma |2 NLM | |
| 650 | 7 | |a Hypoglycemic Agents |2 NLM | |
| 650 | 7 | |a Cholesterol |2 NLM | |
| 650 | 7 | |a 97C5T2UQ7J |2 NLM | |
| 700 | 1 | |a Li, Yining |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Yexiang |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Chang |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Weizhi |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Xiaowan |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Yinghong |e verfasserin |4 aut | |
| 700 | 1 | |a Lei, Lijuan |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Xinhai |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yuyan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yuhao |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Shunwang |e verfasserin |4 aut | |
| 700 | 1 | |a Hong, Bin |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Chao |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Yanni |e verfasserin |4 aut | |
| 700 | 1 | |a Si, Shuyi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie |d 1984 |g 172(2024) vom: 27. März, Seite 116220 |w (DE-627)NLM012645591 |x 1950-6007 |7 nnns |
| 773 | 1 | 8 | |g volume:172 |g year:2024 |g day:27 |g month:03 |g pages:116220 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.biopha.2024.116220 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 172 |j 2024 |b 27 |c 03 |h 116220 | ||